The Use of the RELiZORB Immobilized Lipase Cartridge in Enterally-Fed Children With Cystic Fibrosis: A Retrospective Case Series. Issue 4 (October 2022)

• Record Type: Journal Article
• Authors: Baghae Pour, Parasto; Gregg, Shannon; Coakley, Kathryn E.; Caffey, L. Francine; Cohen, Deborah; Myers, Orrin B.; Gonzales-Pacheco, Diana
• Is Part Of: Topics in clinical nutrition. Volume 37:Issue 4(2022)
• Page Start: 266
• Page End: 275
• Publication Date: 2022-10
• Subjects: cystic fibrosis -- enteral nutrition -- fat malabsorption -- pancreatic enzyme replacement therapy -- pancreatic insufficiency -- RELiZORB immobilized lipase cartridge; Nutrition -- Periodicals; Diet therapy -- Periodicals; Children -- Nutrition -- Periodicals; 613.2
• DOI: 10.1097/TIN.0000000000000300
• Languages: English
• ISSNs: 1550-5146

Abstract

Abstract : The objective of this retrospective study was to evaluate the impact of the RELiZORB immobilized lipase cartridge with overnight enteral nutrition (EN) on body mass index (BMI) or weight-for-length percentile, stool quality, and gastrointestinal (GI) symptoms in children with cystic fibrosis (CF) and pancreatic insufficiency. Frequency of diarrhea, steatorrhea, and malodorous stools significantly decreased at final visit compared with baseline ( P = .008, P = .004, P = .031, respectively). Improved BMI or weight-for-length percentile was observed in 10 out of 16 participants; however, the change was not significant. RELiZORB use decreased frequency of most GI symptoms in pediatric patients with CF on EN.